TIDMAPH

RNS Number : 3294U

Alliance Pharma PLC

01 April 2021

 
 For immediate release                                             1 April 2021

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 31 March 2021 the Company's issued share capital consists of 534,011,603 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 534,011,603 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Hannah Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Oliver Steele 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUPUQWCUPGGUG

(END) Dow Jones Newswires

April 01, 2021 06:39 ET (10:39 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.